E. Dam

发表

Selective-Advantage Profile of Human Immunodeficiency Virus Type 1 Integrase Mutants Explains In Vivo Evolution of Raltegravir Resistance Genotypes

F. Clavel, R. Quercia, E. Dam, 2009, Journal of Virology.

Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors

V. Calvez, F. Brun-Vézinet, B. Masquelier, 2001, Antimicrobial Agents and Chemotherapy.

Predictive Values of the Human Immunodeficiency Virus Phenotype and Genotype and of Amprenavir and Lopinavir Inhibitory Quotients in Heavily Pretreated Patients on a Ritonavir-Boosted Dual-Protease-Inhibitor Regimen

F. Clavel, G. Chêne, A. Barrail-Tran, 2008, Antimicrobial Agents and Chemotherapy.

Long-Term Foscarnet Therapy Remodels Thymidine Analogue Mutations and Alters Resistance to Zidovudine and Lamivudine in HIV-1

F. Clavel, Louise Joergensen, J. Gerstoft, 2006, Antiviral therapy.

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.

S. Paulous, F. Clavel, V. Obry, 1999, AIDS.

Synergistic Inhibition of Protease-Inhibitor-Resistant HIV type 1 by Saquinavir in Combination with Atazanavir or Lopinavir

L. Essioux, F. Clavel, A. Hill, 2006, Antiviral therapy.

PKR Stimulates NF-κB Irrespective of Its Kinase Function by Interacting with the IκB Kinase Complex

E. Meurs, R. Weil, A. Hovanessian, 2000, Molecular and Cellular Biology.

Identification of V3 Loop-binding Proteins as Potential Receptors Implicated in the Binding of HIV Particles to CD4+Cells*

E. Dam, J. Blanco, S. Muller, 1998, The Journal of Biological Chemistry.

Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type

F. Clavel, A. Hance, D. Lecossier, 2009, Retrovirology.

Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss

H. Kräusslich, B. Glass, F. Clavel, 2009, PLoS pathogens.

Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study.

J. Gehl, L. Mir, C. Robert, 2013, Human gene therapy. Clinical development.

Quantification of the Effects on Viral DNA Synthesis of Reverse Transcriptase Mutations Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Analogues

F. Mammano, F. Clavel, A. Hance, 2005, Journal of Virology.

Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors

V. Trouplin, F. Mammano, F. Clavel, 2003, Journal of Virology.

Low Genetic Barrier to Large Increases in HIV-1 Cross-Resistance to Protease Inhibitors during Salvage Therapy

C. Charpentier, F. Clavel, G. Chêne, 2006, Antiviral therapy.

Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients

F. Clavel, P. Clevenbergh, J. Schmit, 2002, HIV clinical trials.